CMPS vs. ATAI

In the year-to-date period, CMPS achieves a -54.63% return, which is significantly lower than ATAI's -15.60% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for COMPASS Pathways plc (CMPS) and Atai Life Sciences N.V. (ATAI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current CMPS Sharpe Ratio is -0.66, which is lower than the ATAI Sharpe Ratio of -0.11. The chart below compares the historical Sharpe Ratios of CMPS and ATAI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither CMPS nor ATAI has paid dividends to shareholders.

The maximum CMPS drawdown since its inception was -93.38%, roughly equal to the maximum ATAI drawdown of -94.77%. Use the drawdown chart below to compare losses from any high point for CMPS and ATAI. For additional features, visit the drawdowns tool.

COMPASS Pathways plc (CMPS) and Atai Life Sciences N.V. (ATAI) have volatilities of 19.69% and 19.61%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between COMPASS Pathways plc and Atai Life Sciences N.V.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.